Transversus Abdominis Plane Block During Kidney Transplant Surgery

University Hospital Center (CHU) Dijon Bourgogne

Status and phase

Completed

Phase 4

Conditions

Kidney Transplant

Treatments

Drug: 0.9% sodium chloride BAXTER

Drug: Ropivacaine 500mg/100ml Naropeine

Study type

Interventional

Funder types

Other

Identifiers

NCT02080728

Jazayeri-Steinmetz AOI 2012

Details and patient eligibility

About

The surgeon places the catheter in the thickness of the oblique internal and transverse muscles at the moment the wall is closed, under visual control. A multiperforated catheter whose length corresponds to that of the incision is chosed. The catheter will deliver one of two products chosen at random: either ropivacaine or placebo.

This study will evaluate postoperative pain during the first 24 hours thanks to a recognized indicator the VAS (Visual Analogue pain Scale). The total consumption of analgesics will also be recorded, starting with the titration of morphine in the post-op room, and then the consumption of classical analgesics in the nephrology department. These will only be given if the VAS score is equal to 4 or above.

This is a prospective, single-centre, controlled, double blind study of ropivacaïne 0.2% versus placebo in continuous TAP block during the first 24 hours after the operation in patients undergoing kidney transplant surgery.

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient opéré for kidney transplant
Patients who have provided written informed consent
Patients with national health insurance cover
Patients aged 18 years and above

Exclusion criteria

Pregnant or breast-feeding women
allergies/hypersensitivity to paracetamol (or propacetamol chlorhydrate (paracetamol pro-drug) or one of its excipients), to local anesthetics, morphines (or other constituents)
patients under guardianship or ward of court